Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?

Table 3 Multivariate analysis (Cox proportional hazards regression model) to identify factors influencing the survival

	Odds ratio	95% CI	Pvalue
Age > 66 (yr)	0.284	0.077-1.044	NS (P = 0.058)
Gender: female	3.995	0.704-22.662	NS (P = 0.118)
Resistance to TACE	8.264	1.770-38.461	P = 0.007
AFP > 200 (ng/mL)	0.385	0.121-1.230	NS (P = 0.107)
DCP > 200 (mAU/mL)	1.181	0.218-6.390	NS (P = 0.847)
Albumin > 3.5 (g/dL)	0.012	0.001-0.181	P = 0.001
Total bilirubin > 1.0 (mg/dL)	4.000	1.004-15.933	P = 0.049
PT (INR) > 1.20	0.490	0.155-1.551	NS (P = 0.225)
ALT > 50 (U/L)	1.229	0.378-3.999	NS (P = 0.732)
Plt > 15.0 (× 104/μL)	1.251	0.330-4.736	NS (P = 0.742)
Number of tumors > 6	0.403	0.090-1.794	NS (P = 0.233)
Size of the largest tumor > 5.0 cm	0.913	0.215-3.884	NS (P = 0.902)
Clinical stage: IVA	13.800	1.638-116.257	P = 0.016
Response to HAIC: CR, PR	0.024	0.004-0.160	P = 0.0001
Child-Pugh: B	0.251	0.019-3.307	NS (P = 0.293)
Hepatic encephalopathy: presence	0.643	0.123-3.347	NS (P = 0.599)
Ascites: presence	3.471	0.835-14.419	NS (P = 0.087)

TACE: Transarterial chemoembolization; AFP: α-fetoprotein; DCP: Des-γ-carboxyprothrombin; PT: Prothrombin time; INR: International ratio; ALT: Alanine aminotransferase; HAIC: Hepatic arterial infusion chemotherapy; CR: Complete response; PR: Partial response; CI: Confidence interval.